30 March 2021
Rymarz Zdort advised ExploRNA Therapeutics in the process of an equity investment that involved a subscription for shares in ExploRNA Therapeutics by the fund Black Forest SICAV-SIF (owned by Michał Sołowow) and the provision of funds for the expansion of the former’s operations.
ExploRNA Therapeutics is a biotech spin-off company of the University of Warsaw, which develops ground-breaking mRNA modification technologies paving the way for new therapeutic applications of mRNA in medicine, such as COVID-19 vaccines.
Black Forest SICAV-SIF is an investment fund supporting scientific and technological advancements achieved by both Polish and foreign companies. Active in a number of industries and sectors, Black Forest’s net asset value has now exceeded EUR 4.1 billion. Products manufactured by its companies are sold throughout the world (in more than 60 countries, in six continents).
The investment by Black Forest SICAV-SIF will allow ExploRNA Therapeutics to develop and implement an ambitious research program focusing on the use of mRNA for therapeutic purposes and enhancing the company’s research potential.
24 November 2023
The Lawyer European Awards 2023 We are pleased to announce that our law firm has been recognised in this year’s edition of a competition aimed at acknowledging the best law firms in Europe organise...
15 November 2023
We are pleased to announce that we advised Stokado on the acquisition of the self-storage rental company Top Box. Stokado's current leasable space stands at over 20,000 square metres. The acquisition ...
9 November 2023
The law firm of Rymarz Zdort Maruta, in line with its strategy, is continuing its dynamic growth by expanding the scope of support it provides to also cover the Life Sciences sector. Over the coming m...
